Document link: Preliminary Recommendation on Vasopressin (Proponents may submit appeals to hta@doh.gov.ph until 25 February 2022.) Document Preview:
Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Document link: Preliminary Recommendation on Pertuzumab for HER2+ breast cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview:
Preliminary Recommendation for the Inclusion of Sambong 250mg Tablets as Anti-Urolithiasis
Document link: MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) (Proponents may submit appeals to hta@doh.gov.ph until 04 January 2022 using the prescribed appeal form.) Document Preview:
Preliminary Recommendation on Dolutegravir (DTG)
Document link: MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) (Proponents may submit appeals to hta@doh.gov.ph until 10 September 2021.) Document Preview:
Preliminary Recommendation on Tenofovir/Lamivudine/Dolutegravir (TLD)
Document link: MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) (Proponents may submit appeals to hta@doh.gov.ph until 23 August 2021.) Document Preview: